Furthermore, to evaluate the capacity of BLVRB to monitor pharmacotherapeutic effects specifically targeting IPH, plasma BLVRB levels were assessed in a preclinical atherosclerotic mouse vein graft model of unstable atherosclerosis subject to antiangiogenic treatment targeting IPH. The gene discussed is BLVRB; the disease is atherosclerosis.